TerminatedPhase 2NCT01675154
Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia
Studying Familial chylomicronemia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Texas Southwestern Medical Center
- Principal Investigator
- Abhimanyu Garg, MDUniversity of Texas Southwestern Medical Center
- Intervention
- SLx-4090 placebo(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 12-100 years · All sexes
- Timeline
- 2015 – 2020
Study locations (2)
- UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01675154 on ClinicalTrials.govOther trials for Familial chylomicronemia syndrome
Additional recruiting or active studies for the same condition.